Acute Coronary Syndrome (ACS): This combination is indicated to reduce the risk of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS, including unstable angina (UA) and non–ST-elevation myocardial infarction (NSTEMI), as well as in patients with ST-segment elevation myocardial infarction (STEMI).

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: In patients with a recent history of myocardial infarction or stroke, or those with established peripheral arterial disease, this combination is used to lower the risk of myocardial infarction and stroke.

Clopidogrel is a prodrug that inhibits platelet activation and aggregation by irreversibly binding its active metabolite to the P2Y12 ADP receptor on platelets. Platelet inhibition begins within 2 hours after a single oral dose. With repeated daily dosing of 75 mg, inhibition increases from the first day and reaches a steady state between Day 3 and Day 7.

Aspirin inhibits platelet aggregation through irreversible inhibition of cyclooxygenase (COX), thereby reducing the formation of thromboxane A2, a key mediator of platelet aggregation and vasoconstriction.

Pharmacokinetics: After repeated oral dosing of 75 mg clopidogrel, plasma levels of the parent drug are very low and often below measurable limits after 2 hours. Clopidogrel is extensively metabolized in the liver. The main circulating metabolite is an inactive carboxylic acid derivative, accounting for about 85% of circulating compounds. Approximately 50% of clopidogrel metabolites are excreted in urine and about 46% in feces within 5 days. The elimination half-life of the main metabolite is about 8 hours. Food does not significantly affect its bioavailability.

Absorption and Distribution: Clopidogrel is rapidly absorbed after oral administration, with peak plasma levels reached approximately 1 hour after dosing. Plasma concentrations increase proportionally with doses between 50–150 mg. At least 50% absorption is indicated based on urinary excretion. Clopidogrel and its main metabolite are highly protein-bound (98% and 94%, respectively).

Metabolism and Elimination: Clopidogrel undergoes rapid hydrolysis to form its inactive carboxylic acid derivative. The glucuronide form of this metabolite is also found in plasma and urine.

The recommended dose of Clopidogrel is 75 mg once daily with or without food. No dosage adjustment is necessary for elderly patients or patients with renal patients. For patients with acute coronary syndrome (unstable angina/non-Q-wave MI), Clopidogrel should be initiated with a single 300 mg loading dose and then continued at 75 mg once daily. Aspirin (75 mg-325 mg once daily) should be initiated and continued in combination with Clopidogrel. In studies it was found that most patients with acute coronary syndrome also received heparin acutely.

Studies have evaluated potential drug interactions with this combination:

Aspirin: Aspirin does not alter the clopidogrel-mediated inhibition of ADP-induced platelet aggregation. However, clopidogrel enhances aspirin-induced inhibition of collagen-mediated platelet aggregation.

Heparin: Clopidogrel does not require dose adjustment of heparin nor does it significantly alter heparin’s anticoagulant effect. However, concurrent use may increase inhibition of platelet aggregation.

NSAIDs: Combined use with NSAIDs may increase the risk of occult gastrointestinal bleeding. Clopidogrel should be used cautiously with NSAIDs.

Warfarin: The safety of combined use with warfarin has not been well established; therefore, co-administration should be approached with caution.

This combination is contraindicated in patients with known hypersensitivity to any component of the drug and in those with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.

This combination is generally well tolerated.

There are no adequate and well-controlled studies in pregnant women. It may be used during the first and second trimesters if clearly necessary. It is contraindicated during the third trimester. It is not known whether clopidogrel is excreted in human milk, although aspirin is known to be present in breast milk. Breastfeeding should be discontinued during treatment.

This combination may prolong bleeding time. Rare cases of thrombotic thrombocytopenic purpura (TTP) have been reported. Reye’s syndrome may occur in individuals with viral infections or flu-like symptoms. Hypersensitivity reactions, including rash, angioedema, and hematologic abnormalities, have also been reported, especially in patients with prior sensitivity to thienopyridines.

This combination should generally be avoided in children, particularly those under 12 years of age, unless the potential benefit outweighs the risk. Aspirin may contribute to the development of Reye’s syndrome in pediatric patients.

Overdose may lead to prolonged bleeding time due to reduced platelet aggregation. Symptoms may include dizziness, headache, confusion, nausea, vomiting, and gastrointestinal disturbances. Severe cases may result in bleeding, respiratory or circulatory collapse, or renal impairment. Management includes supportive care, monitoring, and in severe cases, platelet transfusion or dialysis.

Antiplatelet drugs

Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.